PCL2 Banner

The immune system can be programmed to recognize and destroy cancerous cells infected by viruses or affected by transforming genetic or epigenetic alterations. If properly activated, a specific immune attack can lead to a long-term remission or even cure. We are witnessing the renaissance of the concept of immune-mediated cancer therapy, and the need of predictive models for its preclinical assessment is at an all-time high.

Cambridge Healthtech Institute’s Tumor Models for Cancer Immunotherapy is designed to feature and discuss cutting-edge complex immunocompetent models for cancer immunotherapy research, as well as to present case studies of their successful applications.

Preliminary Agenda


ADVANCING IMUNOCOMPETENT MODELS AND ASSESSING IMMUNO-ONCOLOGY PROGRAMS 

Preclinical Tumor Models for Evaluating Bispecific Redirected T-cell Therapeutics

Chad May, Ph.D., Director, Oncology Research Unit, Pfizer

 

 

Genetic Engineering of The Mouse Immune System To Test Novel Cancer Immuno-Therapuetics
Gavin Thurston, Ph.D., Vice President, Oncology & Angiogenesis Research, Regeneron Pharmaceuticals

Adoptive Immunotherapy of Cancer Using ex vivo Expanded Vg9Vd2 T-Cells

John Maher, M.D., Ph.D., Senior Lecturer in Immunology, NIHR Biomedical, Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London


TRANSLATIONAL APPROACHES IN IMMUNO-ONCOLOGY 

Joint Presentation: Preclinical to Clinical Translation of Anti-PD-1 Blockade

David Kaufman, M.D., Ph.D., Director/Senior Principal Scientist, Oncology/Immunotherarpy Clinical Research, Merck

Elaine Pinheiro, Ph.D., Associate Principal Scientist, In Vivo Pharmacology – Oncology, Merck Research Laboratories

Translational Approaches to Preclinical Evaluation of Immune Oncology Agents
Brett Hall, Ph.D. Head of TMED Oncology, MedImmune

Breast Cancer Vaccine Clinical Study Design Based on Preclinical Data

Vincent K. Tuohy, Ph.D., Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research; Staff, Department of Immunology, Cleveland Clinic


DESIGNING AND ASSESSING COMBINATIONS 

Identification of Novel Immune-Modulatory Combination through Transcriptomic and Proteomic-Based Analysis of Tumor Models

Daniela Cipolletta, Ph.D., Principal Investigator Immunology, Clinical Trenslational Oncology, Novartis Institutes for Biomedical Research

Combining Radiation Therapy and Cancer Immunotherapy: Preclinical Assessment and Translational Approaches

Maria Angelica Cortez, Ph.D., Postdoctoral fellow, Experimental Radiation Oncology, UT M.D. Anderson Cancer Center


IMAGING IN CANCER IMMUNOTHERAPY RESEARCH 

Imaging the Immune Response to Cancer

Michael Dougan, M.D., Ph.D., Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute

ImmunoPET Imaging in The Development Of Therapeutic Antibodies

Jan Marik, Ph.D., Department of Biomedical Imaging, Genentech, Inc.


For questions about the meeting, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
T: (+1) 973-525-4667
E: mfilshtinsky@healthtech.com 

For sponsorship and exhibit information, contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com 

WPC 

Prelim Agenda  


Arrow Event At A Glance 


Arrow 2014 Final Brochure 


Arrow View All Sponsors 


Arrow View All Media Partners 


SPONSORSHIPS & EXHIBITS

The exhibit hall has sold out the past four years, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Joseph Vacca
Associate Director, Business Development
781-972-5431
jvacca@healthtech.com 

 

 

Testimonials

WPC Quotes